These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11317476)

  • 1. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).
    Appel-Dingemanse S; Hirschberg Y; Osborne S; Pommier F; McLeod J
    Eur J Clin Pharmacol; 2001 Mar; 56(12):889-91. PubMed ID: 11317476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
    Zhou H; Horowitz A; Ledford PC; Hubert M; Appel-Dingemanse S; Osborne S; McLeod JF
    J Clin Pharmacol; 2001 Oct; 41(10):1131-9. PubMed ID: 11583482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
    Appel-Dingemanse S
    Clin Pharmacokinet; 2002; 41(13):1021-42. PubMed ID: 12403641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects.
    Swan SK; Zhou H; Horowitz A; Alladina L; Hubert M; Appel-Dingemanse S; Osborne S; Lambrecht L; McLeod JF
    J Clin Pharmacol; 2003 Apr; 43(4):359-64. PubMed ID: 12723456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.
    Appel-Dingemanse S; Horowitz A; Campestrini J; Osborne S; McLeod J
    Aliment Pharmacol Ther; 2001 Jul; 15(7):937-44. PubMed ID: 11421867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects.
    Krösser S; Tillner J; Fluck M; Ungethüm W; Wolna P; Kovar A
    Int J Clin Pharmacol Ther; 2007 May; 45(5):271-80. PubMed ID: 17542349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist.
    Appel S; Kumle A; Hubert M; Duvauchelle T
    J Clin Pharmacol; 1997 Mar; 37(3):229-37. PubMed ID: 9089425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT
    Nirogi R; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2021 May; 41(5):469-482. PubMed ID: 33788154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
    Zou JJ; Bian XJ; Ding L; Zhu YB; Fan HW; Xiao DW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):151-7. PubMed ID: 18069077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
    Appel-Dingemanse S; Lemarechal MO; Kumle A; Hubert M; Legangneux E
    Br J Clin Pharmacol; 1999 May; 47(5):483-91. PubMed ID: 10336571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.
    Zhou H; Khalilieh S; Svendsen K; Pommier F; Osborne S; Appel-Dingemanse S; Lasseter K; McLeod JF
    J Clin Pharmacol; 2001 Sep; 41(9):987-93. PubMed ID: 11549104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
    Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
    Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration.
    Milton KA; Scott NR; Allen MJ; Abel S; Jenkins VC; James GC; Rance DJ; Eve MD
    J Clin Pharmacol; 2002 May; 42(5):528-39. PubMed ID: 12017347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
    Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).
    Zhou H; Khalilieh S; Lau H; Guerret M; Osborne S; Alladina L; Laurent AL; McLeod JF
    J Clin Pharmacol; 1999 Sep; 39(9):911-9. PubMed ID: 10471981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.